ZURA: Zura Bio Ltd Price to Sales
Despite the aggressive expansion of antibody clinical trials, GURU.Markets provides a linear chart of the revenue multiple, where the current level is . This price action contrasts with stringent FDA regulatory barriers and the complexity of patent development. The internal success of Zura Bio Limited is driven by the management's scientific discipline and efficient capital allocation to achieve breakthrough medical results.
Analytical breakdowns for Zura Bio Limited (ZURA)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
- earnings and valuation multiples indicators:
ZURA - Company Net Income|Expected Net Profit Zura Bio Limited|ZURA - Price to Earnings Ratio|Future Price to Earnings Multiple Zura Bio Ltd|ZURA - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Zura Bio Limited|ZURA - Operating profit EBITDA|Net earnings per share for the last four quarters Zura Bio|ZURA - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months zurabio.com|ZURA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Zura Bio Limited
- sales revenue and business income indicators:
Summary company analytics:Zura Bio Ltd, ZURA
Professional capital evaluates Zura Bio Limited (ZURA) through the lens of its antibodies' potential for treating inflammatory pathologies, benchmarking market value against current revenues. By analyzing the price-to-sales multiple, the investor determines the price of each dollar of revenue, enabling the timely recognition of asset overvaluation and the mitigation of risks associated with a deep drawdown amid inflated expectations for the clinical portfolio.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA: Market Cap to Revenue|Price-to-Sales Ratio PTGX|IMVT (Immunovant, Inc.) - Market Cap to Revenue|kiniksa.com (KNSA) - P/S Multiple|Price-to-Revenue Ratio Grifols|ADPT: Market Capitalization-to-Revenue Ratio|P/S Multiple CLDX|P/S Multiple Aurinia Corp (AUPH)|BioCryst - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio VERA|Dianthus Therapeutics, Inc. - P/S Multiple|PHVS: Price-to-Revenue Ratio|ABCL: P/S Multiple|TRML - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Precigen, Inc.|Price to Sales pharming.com PHAR|Market Cap to Revenue NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Immunome Bio - Price-to-Revenue Ratio|Gossamer Bio, Inc. - P/S Multiple|Price-to-Revenue Coefficient kalvista.com KALV|Septerna (SEPN) - Price-to-Revenue Ratio|Market Cap to Revenue Pieris Pharma|SVRA (Savara Corp) - P/S Multiple|Rigel Corp (RIGL) - Price-to-Revenue Coefficient|Market Cap to Revenue ANAB (AnaptysBio, Inc.)|Market Cap to Sales Volume ATXS|P/S Multiple ENGN (enGene)|RAPT Therapeutics Inc. (RAPT) - Price to Sales|Aerovate - P/S Multiple|ACRS (Aclaris Therapeutics, Inc) - Market Cap to Revenue Ratio|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|Price-to-Sales Ratio TLSA (tizianalifesciences.com)|Market Cap to Revenue CABA|P/S Multiple Ventyx Biosciences Inc.|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|AVTX (Avalo Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ELDN (Eledon Pharmaceuticals)|P/S Multiple agenusbio.com AGEN|CLYM - Price-to-Revenue Ratio|Price-to-Sales Ratio ATYR|ADAG: P/S Multiple|Ikena Oncology - Market Capitalization-to-Revenue Ratio|STTK (Shattuck Labs Inc) - P/S Multiple|P/S Multiple Equillium Bio|Price-to-Revenue Ratio Connect Biopharma (CNTB)|IMUX (immunic-therapeutics.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Atara Bio ATRA|IFRX - Market Cap to Revenue|X4 Pharmaceuticals - P/S Multiple|ACET - P/S Multiple|CELU (celularity.com) - Market Cap to Revenue|INmune Bio Inc - Market Capitalization-to-Revenue Ratio|BRNS (Barinthus Bio) - P/S Multiple|Kezar Life Sciences Inc (KZR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|Market Cap to Revenue akaritx.com AKTX|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|QTTB - Market Cap to Revenue|GOVX: Market Cap to Revenue|EDSA - P/S Multiple|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CARM|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Price to Sales Bolt Bio BOLT|Market Cap to Revenue HCWB (HCW Biologics Inc.)|APVO: Price-to-Sales Ratio|AIM ImmunoTech Inc. - Market Cap to Revenue|P/S Multiple Aditxt Inc. ADTX|GRI - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio XRTX (XORTX Therapeutics Inc)|HIND: P/S Multiple|Revelation Biosciences Corp (REVB) - P/S Multiple|Market Cap to Revenue INDP|SCNI: Market Capitalization-to-Revenue Ratio|P/S Multiple CALI|Price-to-Revenue Ratio AFMD (affimed.com)|P/S Multiple ALLK (Allakos)|Price-to-Revenue Coefficient HOOKIPA Pharma, Inc. (HOOK)|IGMS - Price-to-Revenue Ratio|Price to Sales iteostherapeutics.com|OCEA (Ocean Biomedical) - Market Cap to Revenue|TC BioPharm (Holdings) Plc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Third Harmonic Bio, Inc
